Read on Twitter
1/5 #TumorBoardTuesday
🧬No more waiting! Here’s our summary of @RachelRiechelm2 @jessrzanotti’s talk re: hypermut #NET. Can biomarker become clinically actionable?
🆓#CME: 2 quick❓
ALL CME 🔗: integrityce.com/TBT2023
CME eval🔗: integrityce.com/TBTeval231/5 #TumorBoardTuesday twitter.com/i/web/status/1…
🧬No more waiting! Here’s our summary of @RachelRiechelm2 @jessrzanotti’s talk re: hypermut #NET. Can biomarker become clinically actionable?
🆓#CME: 2 quick❓
ALL CME 🔗: integrityce.com/TBT2023
CME eval🔗: integrityce.com/TBTeval231/5 #TumorBoardTuesday twitter.com/i/web/status/1…
2/5 #TumorBoardTuesday
Case🎀
Take🏠 messages:
✅ Hypermut(TMB>10) RARE in NET
✅ Post-tx w alkylator (CAPE/TEM)
✅Mixed results w IO monotx; studying dual IO, combos
✅ Repeat NGS if NET becomes more aggressive; ID new targets, hypermut
📚The thread: threadreaderapp.com/thread/1653549…
Case🎀
Take🏠 messages:
✅ Hypermut(TMB>10) RARE in NET
✅ Post-tx w alkylator (CAPE/TEM)
✅Mixed results w IO monotx; studying dual IO, combos
✅ Repeat NGS if NET becomes more aggressive; ID new targets, hypermut
📚The thread: threadreaderapp.com/thread/1653549…
3/5 #TumorBoardTuesday
Case🎀
🎥 TBT in a video
@RachelRiechelm2 shared key points:
✅NGS critical in NETs–change substantially over time!
✅Hypermut after CAPE/TEM more common than we think
✅Strategies that use dual IO are under active investigation- may be more effective!
Case🎀
🎥 TBT in a video
@RachelRiechelm2 shared key points:
✅NGS critical in NETs–change substantially over time!
✅Hypermut after CAPE/TEM more common than we think
✅Strategies that use dual IO are under active investigation- may be more effective!
4/5 #TumorBoardTuesday
Case🎀
📷 TBT in an image:
Key mgmt pts & emerging tx for G3 NET.
✅Understand bio of tumor using path, Dotatate, FDG
REPEAT NGS if NET becomes more aggressive.
IO is a next line option, if tumor acquires a hypermut phenotype.
Case🎀
📷 TBT in an image:
Key mgmt pts & emerging tx for G3 NET.
✅Understand bio of tumor using path, Dotatate, FDG
REPEAT NGS if NET becomes more aggressive.
IO is a next line option, if tumor acquires a hypermut phenotype.
5/5 #TumorBoardTuesday
Case🎀
🙏 Can hypermut move from biomarker (aggressive dz) to actionable target- stay tuned!
May is #BladderCancer awareness month!
Join us on May 9, 2023 at 8 PM ET as @PGrivasMDPhD @rafee_talukder present a case of cisplatin-ineligible mUC Tx!
Case🎀
🙏 Can hypermut move from biomarker (aggressive dz) to actionable target- stay tuned!
May is #BladderCancer awareness month!
Join us on May 9, 2023 at 8 PM ET as @PGrivasMDPhD @rafee_talukder present a case of cisplatin-ineligible mUC Tx!
@jaypsv @jgong15 @fedenichetti @OncoThor @OzbayyFatih @RichardKenSuzu1 @RSAGT @SalemGIOncDoc @ferguskeane2 @Juanmaoconnor @KlempnerSam @lavinia_benini @leogilsan @AndresFCardonaZ @Dr_Doc_ @drallysonocean @DrHendifar @fernandbteich @angelobcbrito @AnthonyNguyenMD
@PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio… twitter.com/i/web/status/1…
Remember #TumorBoardTuesday continues to offer CME credit for FREE! Don’t forget to answer the polls👇🏽
Then click this link to quickly request your credit!
CME eval🔗: integrityce.com/TBTeval23
ALL CME 🔗: integrityce.com/TBT2023
Then click this link to quickly request your credit!
CME eval🔗: integrityce.com/TBTeval23
ALL CME 🔗: integrityce.com/TBT2023
https://twitter.com/jessrzanotti/status/1653565130657898496?s=20
• • •
Missing some Tweet in this thread? You can try to
force a refresh
